Clinical Trials
- Gastrointestinal Oncology
- Clinical Trials
Thank you for your interest in GI clinical trials at UCSF.
Research studies conducted with cancer patients are called clinical trials. As a cancer patient, you may take part in a clinical trial.
Please see the links below for current open trials at UC San Francisco. Please note we are currently on an enrollment hold for all GI Studies due to COVID-19. Please reach out to us directly if you have questions about a specific study.
CC#16452: Phase I Study of TAS-102 (Lonsurf) and Radioembolization with 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases
Contact: Alexandra (Alex) Milloy (415) 502-3310: Alexandra.Milloy@ucsf.edu
CC#16702: A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers (MSI-H colorectal carcinomas)
Contact: Dhruba Biswas (415) 514-2259: Dhruba.Biswas@ucsf.edu
CC#174517: Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab in Microsatellite Stable Metastatic Colorectal Cancer
Contact: Renee Wang (415) 514-6258: Renee.Wang@ucsf.edu
CC#189516: A Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Subjects with locally advanced (unresectable) or metastatic solid tumor malignancy including but not limited to SCCHN, NSCLC, metastatic castration resistant prostate cancer (mCRPC), ovarian cancer, colorectal cancer (CRC) and gastric cancer, who have received prior therapy.
Contact: Lauren Wilch (415) 353-3642: Lauren.Wilch@ucsf.edu
CC#187015: A Phase II Study of Preoperative Immunotherapy in Patients with Colorectal Cancer and Resectable Hepatic Metastases
Contact: Marissa Gin (415) 476-3816: Marissa.Gin@ucsf.edu
CC#19457: Phase I/II Trial of Encorafenib, Binimetinib, and Nivolumab in Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer
Contact: Sneha Nalla (415) 353-7284: Sneha.Nalla@ucsf.edu
AMC095: A phase 1 study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors
Contact: Nana Owusu-Kwarteng (415) 514-6363: Nana.Owusu-Kwarteng@ucsf.edu
CC#19958: First-In-Human, Open-Label, Phase I Dose Escalation and Cohort Expansion Study of BB-1701 in Locally Advanced/Metastatic Her2 Expressing Solid Tumors
Contact: Nana Owusu-Kwarteng (415) 514-6363: Nana.Owusu-Kwarteng@ucsf.edu
CC#169521: Combination Therapy of Rucaparib and Irinotecan in Cancers with Mutations in DNA Repair (Note: restricted to patients with defects in the following molecules: BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK2, FANCA, NBN, PALB2, RAD51, RAD51B, RAD51C, RAD51D, RAD54L)
Contact: Lauren Wilch (415) 353-3642: Lauren.Wilch@ucsf.edu
CC#169524: A Pilot Study of Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas
Contact: Melissa Lopez (415) 885-3728: Melissa.Lopez@ucsf.edu
CC#18952: A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies
Contact: Melissa Lopez (415) 885-3728: Melissa.Lopez@ucsf.edu
CC#18956: A Phase 1B Dose Escalation/Expansion Study of Abexinostat in Combination with Pembrolizumab in Patients with Advanced Solid Tumor Malignancies
Contact: Lily Stander (415) 353-4084: Lily.Stander@ucsf.edu
CC#189510: Phase II Trial of AZD6738 Alone and in Combination with Olaparib in Patients with Selected Solid Tumor Malignancies
Contact: Lauren Wilch (415) 353-3642: Lauren.Wilch@ucsf.edu
CC#189513: A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671/V941 as a Monotherapy and IN combination with Pembrolizumab in Participants with KRAS Mutant Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer or Pancreatic Adenocarcinoma
Contact: Lily Stander (415) 353-4084: Lily.Stander@ucsf.edu
CC#189514: A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of RMC-4630 Monotherapy in Adult Participants with Relapsed/Refractory Solid Tumors RMC-4630 is a potent, selective, and orally bioavailable SHP2 allosteric inhibitor that is being developed for patients with tumors harboring certain activating mutations or other genotypic aberrations in the RAS–MAPK pathway, including upstream mutations in RTKs.
Contact: Delaire Fattah (415) 514-9286: Delaire.Fattah@ucsf.edu
CC#189516: A Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Subjects with locally advanced (unresectable) or metastatic solid tumor malignancy including but not limited to SCCHN, NSCLC, metastatic castration resistant prostate cancer (mCRPC), ovarian cancer, colorectal cancer (CRC) and gastric cancer, who have received prior therapy.
Contact: Lauren Wilch (415) 3553-3642: Lauren.Wilch@ucsf.edu
CC#19954: A Phase 1 Multicenter, Open-Label, Dose-Escalation an Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Antitumor Activity of AO_176
Contact: Delaire Fattah (415) 514-9286: Delaire.Fattah@ucsf.edu
CC#19955: Protocol 101-18101 – An Open Label Phase 1b Study of ORIC-101 in Combination with Anticancer Therapy in Patients with Advanced or Metastatic Solid Tumors
Contact: Osman Shokoor (415) 353-8449: Osman.Shokoor@ucsf.edu
CC#19956: Protocol RMC 4360 02: A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of RMC-4630 in combination with Cobimetinib in Adult Participants with Relapsed/Refractory Solid Tumors
Contact: Melissa Lopez (415) 885-3728: Melissa.Lopez@ucsf.edu
CC#17701: A Pilot Study of APX005M in Combination with Concurrent Chemoradiation as Neoadjuvant Therapy for Resectable Esophageal and Gastroesophageal Junction Cancers
Contact: Marissa Gin (415) 476-3816: Marissa.Gin@ucsf.edu
CC#18453: A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of IMAB362 Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-Line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced, Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Contact: Nancy Kaushal (415) 514-7633: Nancy.Kaushal@ucsf.edu
CC#18955: A Phase 1 / 2 Study of Olaparib in Combination with Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Contact: Erika Zigman (415) 353-7381: Erika.Zigman@ucsf.edu
CC#189516: A Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Subjects with locally advanced (unresectable) or metastatic solid tumor malignancy including but not limited to SCCHN, NSCLC, metastatic castration resistant prostate cancer (mCRPC), ovarian cancer, colorectal cancer (CRC) and gastric cancer, who have received prior therapy.
Contact: Lauren Wilch (415) 3553-3642: Lauren.Wilch@ucsf.edu
HEPATOCELLULAR and BILIARY TRACT
CC#15452: A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients with Advanced or Metastatic Cholangiocarcinoma with FGFR2 Gene Fusions or Other FGFR Genetic Alterations Who Failed or Are Intolerant To Platinum-Based Chemotherapy
Contact: Maxine Hamilton (415) 476-3755: Maxine.Hamilton@ucsf.edu
CC#174523: A Multicenter Pilot Study of the Safety, Efficacy, and Immune Cell Profiling in Advanced Hepatocellular Carcinoma (HCC) Patients Treated with the Combination of Sorafenib plus Nivolumab as First-Line of Systemic Therapy
Contact: Karen Zhang (415) 502-1877: Karen.Zhang2@ucsf.edu
CC#184517: A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy
Contact: Maxine Hamilton (415) 476-3755: Maxine.Hamilton@ucsf.edu
CC#194519: A Phase 3 Randomized, Double Blind Study of
Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma
Contact: Gar Singer (415) 353-9544: Gar.Singer@ucsf.edu
S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Contact: Alex Milloy (415) 502-3310: Alexandra.Milloy@ucsf.edu
CC#16702: A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers (MSI-H colorectal carcinomas)
Contact: Dhruba Biswas (415) 514-2259: Dhruba.Biswas@ucsf.edu
CC#17701: A Pilot Study of APX005M in Combination with Concurrent Chemoradiation as Neoadjuvant Therapy for Resectable Esophageal and Gastroesophageal Junction Cancers
Contact: Marissa Gin (415) 476-3816: Marissa.Gin@ucsf.edu
CC#17705: A Pilot Study of Pembrolizumab and Liver Directed Therapy or Peptide Receptor Radionuclide Therapy for Patients with Well-Differentiated Neuroendocrine Tumors and Symptomatic and/or Progressive Metastases.
Contact: Eliot Lee (415) 476-1044: Eliot.Lee@ucsf.edu
CC#187011: A Phase 1/1b Multicenter Study to Evaluate the Humanized Anti-CD73 Antibody, CPI-006, as a Single Agent or in Combination with Ciforadenant, with Pembrolizumab, and with Ciforadenant Plus Pembrolizumab in Adult Subjects with Advanced Cancers
Contact: Eliot Lee (415) 476-1044: Eliot.Lee@ucsf.edu
CC#169524: A Pilot Study of Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas
Contact: Melissa Lopez (415) 885-3728: Melissa.Lopez@ucsf.edu
CC#17459: Phase II Randomized Embolization Trial for Neuroendocrine Tumor Metastases to the Liver (RETNET)
Contact: Shawn Cheng (415) 514-7632: Shawn.Cheng@ucsf.edu
CC#17705: A Pilot Study of Pembrolizumab and Liver-Directed Therapy or Peptide Receptor Radionuclide Therapy for Patients with Well-Differentiated Neuroendocrine Tumors and Symptomatic and/or Progressive Metastases
Contact: Eliot Lee (415) 476-1044: Eliot.Lee@ucsf.edu
A021602: Randomized, Double-Blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumors after Progression on Everolimus (CABINET)
Contact: Alexandra (Alex) Milloy (415) 502-3310: Alexandra.Milloy@ucsf.edu
CC#124512: Banking of Human Biological Specimens for Hepatobiliary Cancer Research Studies: UCSF Hepatobiliary Tissue Bank and Registry
Contact: Karen Zhang (415) 502-1877: Karen.Zhang2@ucsf.edu
CC#134510: GIMP: Molecular Profiling
Contact: Dalila Stanfield (415) 476-2976: Dalila.Stanfield@ucsf.edu
CC#134510: GIMP: Tissue GIMP & Blood GIMP (Collisson)
Contact: Karen Zhang (415) 502-1877: Karen.Zhang2@ucsf.edu
CC#134510: GIMP: PRRT in pNET
Contact: Karen Zhang (415) 502-1877: Karen.Zhang2@ucsf.edu
CC#154520: Lifestyle and Outcomes after Gastrointestinal Cancer: A Prospective Cohort Study (LOGIC)
Contact: Dalila Stanfield (415) 476-2976: Dalila.Stanfield@ucsf.edu
CC#164519: Circulating Tumor Derived Cell-Free DNA as a Novel Biomarker to Predict Recurrence of Colorectal Cancer
Contact: Faaiz Ibrahim (415) 514-8101: Faaiz.Ibrahim@ucsf.edu
CC#174525: Self-Monitoring and Reminder Texts for Physical Activity after Cancer II (Smart Pace II)
Contact: Alexandra (Alex) Milloy (415) 502-3310: Alexandra.Milloy@ucsf.edu
CC#174527: GO – Gut Microbiome and Oral Fluoropyrimidine Study in Patients with Colorectal Cancer
Contact: Dalila Stanfield (415) 476-2976: Dalila.Stanfield@ucsf.edu
CC#174535: A 5-year Longitudinal Observational Study of the Natural History and Management of Patients with Hepatocellular Carcinoma
Contact: Karen Zhang (415) 502-1877: Karen.Zhang2@ucsf.edu
CC#174512: WO39608: A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (MORPHEUS-Pancreatic Cancer)
Contact: Nancy Kaushal (415) 514-7633: Nancy.Kaushal@ucsf.edu
CC#187011: A Phase 1/1b Multicenter Study to Evaluate the Humanized Anti-CD73 Antibody, CPI-006, as a Single Agent or in Combination with Ciforadenant, with Pembrolizumab, and with Ciforadenant Plus Pembrolizumab in Adult Subjects with Advanced Cancers
Contact: Eliot Lee (415) 476-1044: Eliot.Lee@ucsf.edu
CC#189513: A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671/V941 as a Monotherapy and IN combination with Pembrolizumab in Participants with KRAS Mutant Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer or Pancreatic Adenocarcinoma
Contact: Lily Stander (415) 353-4084: Lily.Stander@ucsf.edu
**************************************************
**TO BE OPENED WITHIN 3 MONTHS**
CC#194514: A Phase 2 Multicenter, Open-Label, Non-Randomized Study of Bavituximab Plus Pembrolizumab in Patients with Advanced Gastric or Gastroesophageal Cancer Who Have Progressed On or After At Least One Prior Standard Therapy
Contact: Taylor Sanchez (415) 885-7740: Taylor.Sanchez@ucsf.edu
CC#19801: Digital Symptom Tracking, Patient Engagement and Quality of Life in Advanced Cancer
Contact: Taylor Sanchez (415) 885-7740: Taylor.Sanchez@ucsf.edu
CC#20456: Precision Promise Platform Trial For Metastatic Pancreatic Cancer
Contact: Mikaela Esquivel (415) 353-7145: Mikaela.Esquivel@ucsf.edu
CC#199511: Phase 1/2 Study of CYT-0851 (a RAD51 inhibitor) in Pts. w/Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors
Contact: Lauren Wilch (415) 353-3642: Lauren.Wilch@ucsf.edu
CC#199516: Phase 1/1b Study of TPST-1120 () as Single Agent or w/Systemic Anti-Cancer Therapies in Pts w/Advanced Solid Tumors
Contact: Lily Stander (415) 353-4084: Lily.Stander@ucsf.edu
CC#199512: Phase 1b Master Protocol Studying AMG510 in Subjects w/Advanced Solid Tumors w/KRAS G12C Mutation
Contact: Erika Zigman (415) 353-7381: Erika.Zigman@ucsf.edu
For information on Early Phase clinical trials not listed please contact:
Kamran Abri Lavasani (415) 514-6245: Kamran.AbriLavasani@ucsf.edu
For information on Immunotherapy trials not listed please contact: Andrew Chon (415) 476-2351: Andrew.Chon@ucsf.edu